Regeneron (REGN)
635.66
+6.93 (1.10%)
Upcoming Events
Latest Headlines
Regeneron to present clinical data at medical conferences
June 4, 2026 7:00 AM - StreetInsider
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
June 4, 2026 7:00 AM - StreetInsider
WHO recommends Regeneron antibody for Bundibugyo Ebola outbreak
May 28, 2026 4:01 PM - StreetInsider
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
May 28, 2026 4:00 PM - StreetInsider
Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG
May 27, 2026 8:37 AM - StreetInsider
Important Notice to Long-Term Shareholders of Molina Healthcare, Inc. (NYSE: MOH); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASD
May 26, 2026 8:18 AM - StreetInsider
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)
May 25, 2026 11:33 AM - StreetInsider
Regeneron's Otarmeni gains EMA review for genetic hearing loss
May 22, 2026 7:01 AM - StreetInsider
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
May 22, 2026 7:00 AM - StreetInsider
Regeneron reports positive linvoseltamab results in rare blood disorder
May 21, 2026 5:02 PM - StreetInsider
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
May 21, 2026 5:01 PM - Globe NewsWire
Regeneron Pharma (REGN) PT Lowered to $875 at Canaccord
May 19, 2026 6:38 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $860 at Wolfe Research
May 18, 2026 3:46 PM - StreetInsider
Regeneron (REGN) call put ratio 1 call to 1.2 puts as share price down 9.9%
May 18, 2026 3:35 PM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $785 at Cantor Fitzgerald on Disappointing Trial Results
May 18, 2026 8:59 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $850 at JPMorgan
May 18, 2026 8:07 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $855 at Piper Sandler Following Setback
May 18, 2026 7:45 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $730 at BMO Capital Following LAG-3 Miss
May 18, 2026 7:40 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $861 at Bernstein SocGen Group
May 18, 2026 7:24 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $700 at Wells Fargo
May 18, 2026 7:02 AM - StreetInsider
Regeneron partners with Parabilis for $125M antibody conjugate deal
May 18, 2026 7:01 AM - StreetInsider
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
May 18, 2026 7:00 AM - Globe NewsWire
Regeneron shares fall 12% on disappointing melanoma trial data
May 18, 2026 6:18 AM - StreetInsider
Leerink Partners Downgrades Regeneron Pharma (REGN) to Market Perform, 'on LAG-3 Failure and Eylea Erosion Risk'
May 18, 2026 6:05 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $778 at Truist Securities
May 18, 2026 5:21 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $707 at RBC Capital
May 18, 2026 5:14 AM - StreetInsider
Citi Downgrades Regeneron Pharma (REGN) to Neutral
May 18, 2026 3:18 AM - StreetInsider
BofA Securities Reiterates Buy Rating on Regeneron Pharma (REGN)
May 18, 2026 1:01 AM - StreetInsider
Regeneron melanoma drug trial fails to meet primary endpoint
May 15, 2026 8:19 PM - StreetInsider
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
May 15, 2026 8:19 PM - Globe NewsWire
UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
May 15, 2026 5:56 PM - Globe NewsWire
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
May 15, 2026 4:27 PM - Globe NewsWire
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
May 15, 2026 2:09 PM - Globe NewsWire
Biologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical Tourism
May 15, 2026 10:15 AM - StreetInsider
Form 13F-HR REGENERON PHARMACEUTICAL For: Mar 31
May 8, 2026 4:11 PM - SEC Filing
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
May 8, 2026 7:00 AM - Globe NewsWire
Biotech’s Next Wave May Already be in Motion
May 7, 2026 8:45 AM - Globe NewsWire
Dupixent shows improved esophageal function in phase 4 trial for EoE
May 5, 2026 7:01 AM - StreetInsider
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
May 5, 2026 7:00 AM - Globe NewsWire
Form 4 REGENERON PHARMACEUTICAL For: May 01 Filed by: RYAN ARTHUR F
May 4, 2026 4:15 PM - SEC Filing
Regeneron Pharma (REGN) PT Raised to $995 at Guggenheim
April 30, 2026 2:49 PM - StreetInsider
Form SCHEDULE 13G REGENERON PHARMACEUTICAL Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 1:03 PM - SEC Filing
Regeneron Pharma (REGN) PT Lowered to $762 at RBC Capital
April 30, 2026 8:43 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $800 at Wells Fargo
April 30, 2026 8:35 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $788 at Morgan Stanley
April 30, 2026 7:58 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $916 at Bernstein SocGen Group
April 30, 2026 7:34 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $917 at Barclays
April 30, 2026 6:02 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $769 at Truist Securities
April 29, 2026 4:21 PM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $902 at Raymond James
April 29, 2026 12:35 PM - StreetInsider
Regeneron beats first quarter estimates on Dupixent strength
April 29, 2026 6:55 AM - StreetInsider
Form 10-Q REGENERON PHARMACEUTICAL For: Mar 31
April 29, 2026 6:55 AM - SEC Filing
Form 8-K REGENERON PHARMACEUTICAL For: Apr 29
April 29, 2026 6:50 AM - SEC Filing
Regeneron (REGN) Tops Q1 EPS by 50c, Beats on Revenue
April 29, 2026 6:31 AM - StreetInsider
Regeneron Reports First Quarter 2026 Financial and Operating Results
April 29, 2026 6:30 AM - Globe NewsWire
U.S. Biotech stocks: Q1 earnings previews
April 26, 2026 8:00 PM - StreetInsider
Form ARS REGENERON PHARMACEUTICAL For: Dec 31
April 24, 2026 4:14 PM - SEC Filing
Form DEF 14A REGENERON PHARMACEUTICAL For: Jun 12
April 24, 2026 4:06 PM - SEC Filing
Form DEFA14A REGENERON PHARMACEUTICAL
April 24, 2026 4:05 PM - SEC Filing
Piper Sandler on Regeneron Pharma (REGN): 'Channel Checks Point to Branded Anti-VEGF Expansion'
April 24, 2026 9:00 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $913 at Bernstein SocGen
April 24, 2026 8:34 AM - StreetInsider
Regeneron agrees to lower drug prices, offer gene therapy for free
April 23, 2026 3:46 PM - StreetInsider
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
April 23, 2026 3:46 PM - Globe NewsWire
Regeneron to offer prescriptions at most favored nation prices, Trump says
April 23, 2026 3:25 PM - StreetInsider
Regeneron wins FDA approval for gene therapy treating rare hearing loss
April 23, 2026 12:53 PM - StreetInsider
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
April 23, 2026 12:40 PM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $960 at TD Cowen
April 23, 2026 6:34 AM - StreetInsider
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
April 22, 2026 5:30 PM - StreetInsider
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
April 22, 2026 5:30 PM - StreetInsider
Raymond James Reiterates Outperform Rating on Regeneron Pharma (REGN)
April 22, 2026 2:56 PM - StreetInsider
Regeneron submits U.S. application for gMG drug cemdisiran
April 21, 2026 10:30 AM - StreetInsider
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
April 21, 2026 10:30 AM - StreetInsider
Regeneron Announces Investor Conference Presentations
April 20, 2026 4:05 PM - StreetInsider
Goldman Sachs sees nearly 140% upside in this biopharma stock
April 20, 2026 7:30 AM - StreetInsider
Regeneron and Telix form $2.1 billion radiopharmaceutical partnership
April 13, 2026 6:31 AM - StreetInsider
Telix and Regeneron Announce Strategic Radiopharma Collaboration
April 13, 2026 6:30 AM - Globe NewsWire
Regeneron and Telix Announce Strategic Radiopharma Collaboration
April 13, 2026 6:30 AM - Globe NewsWire
Bernstein on US Pharma and Biotech: Who might buy whom?
April 13, 2026 5:52 AM - StreetInsider
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
April 13, 2026 1:00 AM - StreetInsider
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
April 13, 2026 1:00 AM - StreetInsider
Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)
April 10, 2026 8:51 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $796 at Morgan Stanley
April 10, 2026 8:16 AM - StreetInsider
Regeneron Pharma (REGN) Reiterated at Overweight by Cantor Fitzgerald Ahead of Q1 Call
April 8, 2026 8:00 AM - StreetInsider
Regeneron Pharma (REGN) PT Lowered to $921 at Bernstein SocGen
April 8, 2026 7:59 AM - StreetInsider
Form 8-K REGENERON PHARMACEUTICAL For: Apr 08
April 8, 2026 7:06 AM - SEC Filing
Raymond James on Regeneron Pharma (REGN): 'New Survey Indicates 1Q26 Uptick for Eylea HD, More to Come'
April 8, 2026 5:07 AM - StreetInsider
Regeneron Pharma (REGN) PT Raised to $779 at RBC Capital
April 7, 2026 9:02 AM - StreetInsider
Form 4 REGENERON PHARMACEUTICAL For: Apr 01 Filed by: RYAN ARTHUR F
April 3, 2026 4:01 PM - SEC Filing
Regeneron invests up to $200 million in TriNetX health data partnership
April 2, 2026 4:31 PM - StreetInsider
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
April 2, 2026 4:30 PM - PR NewsWire
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
April 2, 2026 4:30 PM - StreetInsider
Regeneron: expect to be exempt from the pharma tariffs that it hears are being announced today
April 2, 2026 2:02 PM - StreetInsider
FDA approves EYLEA HD for extended dosing up to 20 weeks
April 2, 2026 12:01 PM - StreetInsider
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
April 2, 2026 12:01 PM - Globe NewsWire
Regeneron Pharma (REGN) PT Lowered to $801 at Truist 'To Refresh Risk/Reward'
March 31, 2026 7:04 AM - StreetInsider
Piper Sandler Assumes Regeneron Pharma (REGN) at Overweight
March 31, 2026 4:02 AM - StreetInsider
Form SCHEDULE 13G/A REGENERON PHARMACEUTICAL Filed by: VANGUARD GROUP INC
March 27, 2026 11:38 AM - SEC Filing
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
March 25, 2026 4:05 PM - Globe NewsWire
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
March 25, 2026 4:05 PM - StreetInsider
Dupixent approved in Japan for bullous pemphigoid treatment
March 24, 2026 4:19 AM - StreetInsider
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
March 24, 2026 2:00 AM - StreetInsider
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
March 24, 2026 2:00 AM - StreetInsider
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Sc
March 10, 2026 9:29 PM - Globe NewsWire
Regeneron Pharma (REGN) PT Raised to $890 at Jefferies
March 10, 2026 5:06 PM - StreetInsider
TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN): "if results are replicated in US, could lead to preferential prescribing"
March 9, 2026 9:59 AM - StreetInsider
Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN) following Ph3 study results
March 9, 2026 9:41 AM - StreetInsider
Regeneron obesity drug shows 19% weight loss in phase 3 trial
March 9, 2026 7:00 AM - StreetInsider
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
March 9, 2026 7:00 AM - StreetInsider
Full Article List
